–Current

PI – “Nanotherapeutics for Treatment of Ocular Infections”
NIH R01 EY025947-01  (09/10/15-08/09/18).

PI – “Vascular Permeability in Ocular Infections”
NIH R01EY024140-03  (01/01/14-12/31/17).

Director, Live Animal Imaging and Functional Analysis Module – “Core Grant for Vision Research” (RE Anderson, PI)
NIH CORE grant P30 EY027125 (9/11-8/20)

–Declined

PI – “Role of innate immune recognition in eye infections”
Oklahoma Center for Advancement in Science and Technology Health Research Grant 2009
Declined due to overlap with funded R01EY012985

–Completed

Co-I – “Condensin Dependent Potentiation of Antibiotics” (Rybenkov, PI [OU Norman])
OCAST HR-14-042 (subaward 7/1/14-6/30/16)

PI – “New Models of Endogenous Bacterial Endophthalmitis”
NIH R21 EY022466-01A1 (12/01/12-11/30/14 + 1 year no-cost extension)

PI – “Mechanisms of Inflammation and Vision Loss in Bacillus Endophthalmitis”
NIH R01 EY012985 (9/1/00-8/30/13 + 1 year no-cost)
NIH R01 EY012985S1 (9/1/12-8/31/13)

Director, Animal Module – “Mentoring Vision Research in Oklahoma” (RE Anderson, PI)
NIH COBRE grant P20RR17703 (9/02-8/12  + 1 year no-cost extension)

Co-I – “CAP37 and Ocular Inflammation” (HA Pereira, PI)
NIH R01 EY015534(9/07-8/12 + 1 year no-cost extension)

PI – “Allergan Zymaxid Time Kill Study”
Allergan Inc., Irvine CA (3/11-3/12)

PI – “Improved Therapeutic Regimens for Post-Traumatic Bacterial Endophthalmitis”
Department of Defense CDMRP W81XWH-07-1-0280 (4/07-3/11 + one year no-cost extension)

PI – “Development of a novel anti-inflammatory treatment for clinical management of endophthalmitis”
Charlesson LLC, Oklahoma City OK (3/11-12/11)

PI – “Allergan USA400 Study”
Allergan Inc., Irvine CA (3/11-12/11)

PI – “Conjunctival Isolate Surveillance Study”
Allergan Inc. (04/01/07-12/31/10)

Director, Animal Resources Module – “Core Grant for Vision Research” (RE Anderson, PI)
NIH CORE grant P30 EY012191 (7/99-6/09+1-year bridge)

PI – “Ocular Toxicity and Release Studies of CLT-003”
Charlesson LLC, Oklahoma City OK — (6/1/09-1/31/10)

PI – “Enhancements for Imaging in Vision Research”
Presbyterian Health Foundation (8/08-7/09)

PI – “Rub vs. No-Rub Regimens of Multipurpose Solutions for Contact Lens Care”
Advanced Medical Optics (10/01/07-09/30/08)

PI – “Efficacy of Vancomycin Against Multidrug-Resistant Staphylococcal Ocular Isolates”
Allergan Inc. (8/06-7/07)

PI – “Effect of Partial Evaporation of Various Contact Lens Multi-Purpose Solutions on Antimicrobial Performance”
Advanced Medical Optics (04/01/07-03/31/08)

PI – “Toward Development of an Endogenous Endophthalmitis Model”
Research to Prevent Blindness Lew R. Wasserman Award (7/06-6/07 + 1 year no-cost extension)

PI – “Effect of Removal of Lens Epithelium in the Capsular Bag After Cataract Extraction in the Albino Rabbit”
Alcon Ltd. Inc. (8/06-3/07)

PI – Research to Prevent Blindness Career Development Award
(8/1/00-7/31/05)

PI – “Technological enhancements for NIH-funded vision research”
NIH 3R01 EY1298503S1 (supplement to R01 EY12985) (7/1/02-6/30/04).

PI – “Electroretinographic equipment for vision research”
OUHSC Presbyterian Health Foundation Equipment Grant (11/1/02-10/31/03).

PI – “The role of bacterial motility in Bacillus cereus endophthalmitis”
Fight For Sight Grant in Aid, Prevent Blindness America (9/1/99-8/31/00).

PI –“The role of toxins in Bacillus cereus endophthalmitis”
OUHSC Medical Alumni Association Research Grant (7/1/99-6/30/00).

PI – “Molecular pathogenesis of Bacillus cereus endophthalmitis”
NIH F32 EY06813 (MS Gilmore preceptor) (4/1/97-3/31/99, 3rd year relinquished due to faculty appointment).